CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA ...Middle East

Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The GEMSTONE-303 study results support sugemalimab in combination with chemotherapy as a new standard first-line treatment for...

Hence then, the article about cstone announces publication of gemstone 303 study results for sugemalimab cejemly in jama was published today ( Tuesday 25/02/2025 - 07:24 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA )

Also on site :

• Finn Wolfhard's 'Stranger Things' SNL Skit Met With Backlash From Fans
• Russian hockey legend Ovechkin refuses to wear LGBT tape
• Who Is Katie Bates’ Husband Travis Clark? What We Know About the Affair Admission